InnoCare Pharma Ltd. (HK:9969)
:9969
Want to see HK:9969 full AI Analyst Report?
Total Valuation
InnoCare Pharma Ltd. has a market cap or net worth of HK$15.98B. The enterprise value is HK$8.96B.
Market CapHK$15.98B
Enterprise ValueHK$8.96B
Share Statistics
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,496,284,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InnoCare Pharma Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.46%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)4.46%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee2.11M
Profits Per Employee574.69K
Employee Count1,089
Asset Turnover0.21
Inventory Turnover1.75
Valuation Ratios
The current PE Ratio of InnoCare Pharma Ltd. is 23.1. InnoCare Pharma Ltd.’s PEG ratio is -0.13.
PE Ratio23.1
PS Ratio8.47
PB Ratio2.52
Price to Fair Value2.52
Price to FCF148.84
Price to Operating Cash Flow154.89
PEG Ratio-0.13
Income Statement
In the last 12 months, InnoCare Pharma Ltd. had revenue of 2.30B and earned 625.84M in profits. Earnings per share was 0.36.
Revenue2.30B
Gross Profit2.01B
Operating Income440.59M
Pretax Income638.77M
Net Income625.84M
EBITDA555.89M
Earnings Per Share (EPS)0.36
Cash Flow
In the last 12 months, operating cash flow was 105.04M and capital expenditures -75.07M, giving a free cash flow of 29.97M billion.
Operating Cash Flow105.04M
Free Cash Flow29.97M
Free Cash Flow per Share0.02
Dividends & Yields
InnoCare Pharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-20.93%
50-Day Moving Average12.74
200-Day Moving Average13.78
Relative Strength Index (RSI)41.25
Average Volume (3m)17.45M
Important Dates
InnoCare Pharma Ltd. upcoming earnings date is Aug 25, 2026, TBA (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date―
Financial Position
InnoCare Pharma Ltd. as a current ratio of 5.83, with Debt / Equity ratio of 24.65%
Current Ratio5.83
Quick Ratio5.71
Debt to Market Cap0.08
Net Debt to EBITDA-9.83
Interest Coverage Ratio8.21
Taxes
In the past 12 months, InnoCare Pharma Ltd. has paid 11.26M in taxes.
Income Tax11.26M
Effective Tax Rate0.02
Enterprise Valuation
InnoCare Pharma Ltd. EV to EBITDA ratio is 25.19, with an EV/FCF ratio of 107.07.
EV to Sales6.10
EV to EBITDA25.19
EV to Free Cash Flow107.07
EV to Operating Cash Flow70.32
Balance Sheet
InnoCare Pharma Ltd. has HK$7.07B in cash and marketable securities with HK$1.80B in debt, giving a net cash position of HK$5.26B billion.
Cash & Marketable SecuritiesHK$7.07B
Total DebtHK$1.80B
Net CashHK$5.26B
Net Cash Per ShareHK$3.52
Tangible Book Value Per ShareHK$4.42
Margins
Gross margin is 90.36%, with operating margin of 19.18%, and net profit margin of 27.24%.
Gross Margin90.36%
Operating Margin19.18%
Pretax Margin27.80%
Net Profit Margin27.24%
EBITDA Margin24.20%
EBIT Margin19.18%
Analyst Forecast
The average price target for InnoCare Pharma Ltd. is HK$19.03, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$19.03
Price Target Upside61.94% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast110.05%
EPS Growth Forecast―